LivaNova PLC (NASDAQ:LIVN) Sees Large Growth in Short Interest

LivaNova PLC (NASDAQ:LIVN) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 2,436,767 shares, an increase of 32.7% from the January 15th total of 1,836,041 shares. Based on an average daily volume of 603,535 shares, the short-interest ratio is presently 4.0 days. Currently, 4.5% of the shares of the company are short sold. Currently, 4.5% of the shares of the company are short sold. Based on an average daily volume of 603,535 shares, the short-interest ratio is presently 4.0 days.

Institutional Investors Weigh In On LivaNova

Several large investors have recently made changes to their positions in LIVN. Hantz Financial Services Inc. grew its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the period. State of Wyoming purchased a new stake in LivaNova in the second quarter worth $31,000. EverSource Wealth Advisors LLC lifted its position in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the last quarter. Quarry LP bought a new position in shares of LivaNova during the 3rd quarter worth $36,000. Finally, UMB Bank n.a. raised its stake in LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LIVN. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a report on Tuesday, December 16th. Mizuho lifted their target price on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Stifel Nicolaus boosted their price target on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, KeyCorp assumed coverage on LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $69.38.

LivaNova Stock Up 3.0%

Shares of NASDAQ:LIVN opened at $65.80 on Monday. The business’s 50 day moving average is $63.62 and its 200 day moving average is $57.60. LivaNova has a 12-month low of $32.48 and a 12-month high of $67.92. The stock has a market cap of $3.59 billion, a price-to-earnings ratio of -16.45 and a beta of 0.97. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.